Share this article Share this article ROCHESTER, N.Y., Jan. 7, 2021 /PRNewswire/ -- OyaGen, Inc. announced today publication in VIRUSES, a peer reviewed journal, of studies carried out by OyaGen in collaboration with NIH/NIAID Integrated Research Facility at Fort Detrick MD. This Study identified OYA1 as a "highly effective" antiviral against several viruses including Ebola and Lassa viruses. Bennett et al., A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.' (2021) About OYA1. OYA1 (a.k.a. sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. The published study results showed that OYA1 was "highly effective" in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID. The data also suggest that OYA1 could be significantly more potent than Gilead Science's remdesivir. In vitro studies showed that when OYA1 is dosed with remdesivir both compounds are markedly more effective inhibiting Ebola virus replication and do so at much lower doses than is needed with either compound alone. OYA1 proved equally effective in stopping Ebola infectivity when it was added at the time of infection or 24 hours after an infection.